![Robert E. Sobol](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Robert E. Sobol
Algemeen Directeur bij Virrx, Inc.
Profiel
Robert E.
Sobol is the founder of IDEC Pharmaceuticals Corp.
He is currently the Chief Executive Officer of Virrx, Inc. He previously served as President & Chief Executive Officer of Corautus Genetics, Inc. from 1996 to 2003, Director-Clinical Science at Sidney Kimmel Cancer Center from 1992 to 1996, and Senior Vice President-Medical & Scientific Affairs at Introgen Therapeutics, Inc. from 2003 to 2008.
He also served as President & Chief Executive Officer of Magnum Therapeutics Corp.
and Chief Executive Officer & Executive Director of Multivir, Inc. Sobol received his undergraduate degree from Boston University and his doctorate from Chicago Medical School.
Actieve functies van Robert E. Sobol
Bedrijven | Functie | Begin |
---|---|---|
Virrx, Inc. | Algemeen Directeur | 01-03-2013 |
Eerdere bekende functies van Robert E. Sobol
Bedrijven | Functie | Einde |
---|---|---|
INTROGEN THERPUT | Hoofd Techniek/Wetenschap/O&O | 24-11-2008 |
Corautus Genetics, Inc.
![]() Corautus Genetics, Inc. Pharmaceuticals: MajorHealth Technology Corautus Genetics Inc. is a biopharmaceutical company, which manufactures gene therapy products for the treatment of cardiac and vascular disease & peripheral vascular disease. It is located in Atlanta, GA. | President | 01-01-2003 |
Sidney Kimmel Cancer Center
![]() Sidney Kimmel Cancer Center Medical/Nursing ServicesHealth Services Part of Sanford Burnham Prebys Medical Discovery Institute, Sidney Kimmel Cancer Center provides medical research services. The company is based in San Diego, CA. Sidney Kimmel Cancer Center was acquired by Sanford Burnham Prebys Medical Discovery Institute on June 23, 2009 for $25 million. | Corporate Officer/Principal | 01-01-1996 |
Multivir, Inc.
![]() Multivir, Inc. BiotechnologyHealth Technology MultiVir, Inc. is a clinical-stage gene therapy company. It develops a pipeline of novel product candidates for the treatment of multiple oncological indications. The company's gene therapy and oncolytic viral technologies target some of cancer's most fundamental molecular defects. It operates through the following operating segment: business of developing novel cancer treatments. The company product candidates employ genetically engineered adenoviruses, herpes simplex viruses and vaccinia viruses to deliver therapeutic genes into tumors. It currently uses the following three different viral platforms in the development programs: adenovirus, or Ad, herpes simplex virus, or HSV, and vaccinia virus, or VV. MultiVir was founded on November 5, 2009 and is headquartered in Houston, TX. | Algemeen Directeur | - |
IDEC Pharmaceuticals Corp.
![]() IDEC Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology IDEC Pharmaceuticals Corp. used to develop and commercialize targeted immunotherapies for the treatment of cancer and autoimmune diseases. The company’s products used to act chiefly through immune system mechanisms, exerting their effect by binding to specific, readily targeted immune cells in the patient’s blood or lymphatic system. The company was headquartered in San Diego, CA. | Oprichter | - |
Opleiding van Robert E. Sobol
Boston University | Undergraduate Degree |
Chicago Medical School | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Bedrijven in privébezit | 7 |
---|---|
Corautus Genetics, Inc.
![]() Corautus Genetics, Inc. Pharmaceuticals: MajorHealth Technology Corautus Genetics Inc. is a biopharmaceutical company, which manufactures gene therapy products for the treatment of cardiac and vascular disease & peripheral vascular disease. It is located in Atlanta, GA. | Health Technology |
Introgen Therapeutics, Inc.
![]() Introgen Therapeutics, Inc. Medical SpecialtiesHealth Technology Introgen Therapeutics, Inc. is a biopharmaceutical company focuses on the discovery, development and commercialization of targeted molecular therapies for the treatment of cancer and other diseases. The company develops molecular therapeutics, immunotherapies, vaccines and nano-particle tumor suppressor therapies to treat a wide range of cancers using tumor suppressors, cytokines and genes. The company maintains integrated research, development, manufacturing, clinical and regulatory departments and operates multiple manufacturing facilities including a commercial scale cGMP manufacturing facility. It was founded in June 1993 and is headquartered in Austin, TX. | Health Technology |
IDEC Pharmaceuticals Corp.
![]() IDEC Pharmaceuticals Corp. Pharmaceuticals: MajorHealth Technology IDEC Pharmaceuticals Corp. used to develop and commercialize targeted immunotherapies for the treatment of cancer and autoimmune diseases. The company’s products used to act chiefly through immune system mechanisms, exerting their effect by binding to specific, readily targeted immune cells in the patient’s blood or lymphatic system. The company was headquartered in San Diego, CA. | Health Technology |
Sidney Kimmel Cancer Center
![]() Sidney Kimmel Cancer Center Medical/Nursing ServicesHealth Services Part of Sanford Burnham Prebys Medical Discovery Institute, Sidney Kimmel Cancer Center provides medical research services. The company is based in San Diego, CA. Sidney Kimmel Cancer Center was acquired by Sanford Burnham Prebys Medical Discovery Institute on June 23, 2009 for $25 million. | Health Services |
Magnum Therapeutics Corp.
![]() Magnum Therapeutics Corp. Pharmaceuticals: MajorHealth Technology Magnum Therapeutics Corp. develops pharmaceutical products. The company is based in San Diego, CA. Magnum Therapeutics was acquired by Introgen Therapeutics, Inc. on January 01, 2004. | Health Technology |
Multivir, Inc.
![]() Multivir, Inc. BiotechnologyHealth Technology MultiVir, Inc. is a clinical-stage gene therapy company. It develops a pipeline of novel product candidates for the treatment of multiple oncological indications. The company's gene therapy and oncolytic viral technologies target some of cancer's most fundamental molecular defects. It operates through the following operating segment: business of developing novel cancer treatments. The company product candidates employ genetically engineered adenoviruses, herpes simplex viruses and vaccinia viruses to deliver therapeutic genes into tumors. It currently uses the following three different viral platforms in the development programs: adenovirus, or Ad, herpes simplex virus, or HSV, and vaccinia virus, or VV. MultiVir was founded on November 5, 2009 and is headquartered in Houston, TX. | Health Technology |
Virrx, Inc. |